DENTSPLY SIRONA Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
XRAY$9.70+1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
(in millions)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(482) | $(204) |
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||
| Depreciation | 99 | 99 |
| Amortization of intangible assets | 162 | 159 |
| Goodwill and intangible asset impairments | 510 | 307 |
| Deferred income taxes | (20) | (107) |
| Stock-based compensation expense | 35 | 33 |
| Other non-cash expense | 36 | 29 |
| Changes in operating assets and liabilities: | ||
| Accounts and notes receivable-trade, net | 19 | (31) |
| Inventories, net | 2 | (45) |
| Prepaid expenses and other current assets | 61 | (52) |
| Other noncurrent assets | (6) | (4) |
| Accounts payable | (6) | (10) |
| Accrued liabilities | (17) | 16 |
| Income taxes | (15) | (6) |
| Other noncurrent liabilities | (4) | 33 |
| Net cash provided by operating activities | 374 | 217 |
| Cash flows from investing activities: | ||
| Capital expenditures | (129) | (109) |
| Cash received on derivative contracts | — | 39 |
| Cash paid on derivative contracts | (12) | — |
| Other investing activities | 1 | 1 |
| Net cash used in investing activities | (140) | (69) |
| Cash flows from financing activities: | ||
| Cash paid for treasury stock | (250) | (150) |
| Proceeds on short-term borrowings | 99 | 68 |
| Cash dividends paid | (95) | (86) |
| Proceeds from long-term borrowings | — | 2 |
| Repayments on long-term borrowings | (8) | (6) |
| Other financing activities, net | (10) | (7) |
| Net cash used in financing activities | (264) | (179) |
| Effect of exchange rate changes on cash and cash equivalents | (8) | (25) |
| Net decrease in cash and cash equivalents | (38) | (56) |
| Cash and cash equivalents at beginning of period | 334 | 365 |
| Cash and cash equivalents at end of period | $296 | $309 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.